<DOC>
	<DOCNO>NCT01074905</DOCNO>
	<brief_summary>This randomise open label trial follow 1 year . 660 adult child 6 month diagnose acute Plasmodium vivax randomise 3 group , either chloroquine , artesunate , chloroquine/primaquine therapy . Participants screen day inclusion follow weekly 8 visit every 4 week week 52 . The primary objective study compare efficacy WHO Thai Ministry Public Health recommend radical curative regimen chloroquine primaquine currently use monotherapy regimens chloroquine artesunate along Thai-Burmese border .</brief_summary>
	<brief_title>Study Treatment Vivax Malaria</brief_title>
	<detailed_description>Considerably less attention pay Plasmodium vivax epidemiology Plasmodium falciparum . In area relatively low unstable transmission , comprise majority P.vivax affect area , vivax malaria predominantly disease child ( Luxemburger et al 1999 ) . Chloroquine long standard treatment vivax malaria . Primaquine recommend radical cure vivax malaria , difficult administer due dose duration side effect . This study aim characterize epidemiologic history compare efficacy 3 antimalarial regimen ( chloroquine , artesunate , chloroquine/primaquine ) plasmodium vivax western Thailand . Chloroquine currently standard treatment Plasmodium vivax . Due long half-life chloroquine , first relapse vivax malaria may delay . In contrast , artesunate short half-life , thus , impact first relapse . It know whether chloroquine reduces overall number relapse , delay first relapse . There many important question biology vivax malaria relevance treatment remain unanswered . For example number relapse per infection ( i.e . per successful inoculation ) predetermine adaptive ? If predetermine suppression first relapse ( chloroquine , mefloquine piperaquine ) reduce total number relapse clear benefit . If adaptive drug simply delay relapse less clear benefit . These various uncertainty illustrate importance detailed comparative longitudinal evaluation . In order characterize biology vivax malaria , necessary compare regimens without primaquine . Because challenge face primaquine prescription ( side effect , toxicity G6PD deficient patient duration treatment ) , commonly deploy along Thai Burma border . In effect , compare usual practice ( non primaquine regimen ) recommend WHO Thai MOPH practice ( use primaquine 14 day ) . The information gather crucial understanding chloroquine effect vivax parasite . This lead future study invariably change way treat vivax malaria .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Adults child &gt; 6 month Weight &gt; 7 kg child Have primaquine since last Pv episode Participant ( parent/guardian &lt; 18 year old ) willing able give write informed consent Microscopic diagnosis Plasmodium vivax monoinfection Ability ( investigator opinion ) willingness patient parent/guardian comply study requirement Exclusion Criteria Allergy artesunate , chloroquine primaquine Severe malaria Patients microscopic diagnosis coinfection Plasmodium falciparum Presence condition judgement investigator would place subject undue risk interfere result study Inability tolerate oral medication Pregnancy Blood transfusion last 3 month Antimalarial last 2 month</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>vivax malaria</keyword>
	<keyword>artesunate</keyword>
	<keyword>chloroquine</keyword>
	<keyword>primaquine</keyword>
	<keyword>relapse</keyword>
</DOC>